Stock market wrap: TSMC, Anthropic, Rocket Lab and an IPO

Item	Figure reported
TSMC	Sixth straight quarter of record profit expected
Anthropic Q3 revenue	Up 45%, to nearly $17 billion
Iambic Therapeutics IPO	Priced at $16 per share, Nasdaq
Rocket Lab Neutron	Debut flight pushed to 2027
Colombia COLCAP	Up 0.44% at close

Artificial intelligence demand, a delayed rocket and a biotech listing shaped the stock market news flow on Wednesday, Oct. 14, according to Investing.com reports.

Key takeaways

• TSMC is expected to post its sixth consecutive record quarterly profit, with the AI boom cited as the driver.
• Anthropic’s third-quarter revenue rose 45% to nearly $17 billion, per Investing.com.
• Rocket Lab shares fell after the company moved Neutron’s first flight to 2027.
• Iambic Therapeutics priced its Nasdaq IPO at $16 per share.

TSMC heads toward another record

Investing.com reports that TSMC is expected to deliver its sixth straight quarter of record profit, with demand tied to the AI build-out credited for the run. A streak of that length sets a high bar. Earnings expectations for the chipmaker are already elevated, so the reaction to the report may depend on how results compare with what the market has priced in, not only on the record itself.

Investors in AI-linked stocks and the suppliers and customers around TSMC will watch the report for confirmation that spending remains strong.

Anthropic’s revenue jumps 45%

Investing.com also reported that Anthropic’s third-quarter revenue rose 45% to nearly $17 billion. The figure is another sign of how quickly AI companies are scaling commercially. It is relevant to public markets because the spending behind these revenues flows to chipmakers, cloud providers and data-center suppliers.

Anthropic is not publicly traded, so the number works as a read-through for AI demand rather than a direct trading input. What to watch next is whether the growth rate holds in coming quarters and how the sector’s public companies describe demand in their own results.

Rocket Lab slides on Neutron delay

Rocket Lab shares fell after the company pushed the debut flight of its Neutron rocket to 2027, according to Investing.com, which ran two items on the move. Launch schedules are a central part of the case for space-sector stocks, and a slip into next year pushes back the timeline for a larger vehicle.

For derivatives traders, a schedule change of this kind is the sort of event that can shift how the market prices risk around a stock. Investors will look for further detail from the company on the new timeline.

Iambic prices IPO at $16

Iambic Therapeutics priced its initial public offering at $16 per share on Nasdaq, Investing.com reported. The pricing adds a biotech name to the U.S. new-issue calendar. The first trading sessions will show how the market values the shares relative to the offer price.

Elsewhere

In Latin America, Colombia’s COLCAP index closed up 0.44%, according to Investing.com. Investing.com also published an explainer on Starshield, SpaceX’s military version of Starlink, and reported that Mexico will require digital platforms to protect minors from violent and sexual content. Neither item carried a market figure.

What to watch

TSMC’s results are the next hard data point for the AI trade. Rocket Lab’s updated Neutron timeline and Iambic’s debut trading will show how investors weigh schedule risk and new-issue appetite.